A Letter to Clients Regarding COVID-19

It goes without saying that we are all facing unprecedented times in the face of the current COVID-19 epidemic. Like you, PathGroup is an essential component of the U.S. healthcare system and we remain fully operational to support the laboratory testing services of you and your patients.

 

To read more, click here.

Test Available: Coronavirus Disease 2019 (COVID-19)

Effective March 16, 2020, PathGroup will begin to offer testing for Coronavirus Disease 2019 (COVID-19).  This test is to be ordered only for individuals who meet the Centers for Disease Control and Prevention (CDC) Coronavirus Disease 2019 (COVID-19) clinical and/or epidemiological criteria for testing.  Because this criteria may change as more is learned about the virus, please refer directly to the CDC website for the most up-to-date patient testing criteria: https://www.cdc.gov/coronavirus/2019-nCoV/hcp/clinical-criteria.html

 

Click here for more information.

It’s Spring Allergy Season!

More than 50 million Americans suffer from allergies every year making allergies the sixth leading cause of chronic illness in the United States. Allergies are a common, yet overlooked, disease and the most common health issue that affects children in the U.S. An estimated 4.2 million children in the U.S. have a food allergy to things like peanuts, eggs, milk, wheat, tree nuts, fish and shellfish.

Click here to learn more!

October is Breast Cancer Awareness Month

Along with our large community of Women’s Health providers, PathGroup recognizes October as Breast Cancer Awareness Month and celebrates the efforts of these healthcare providers in diagnosing and treating women affected by breast cancer.

 1 in 8 women in the United States will develop breast cancer in their lifetime making breast cancer the most common cancer among American women. About 270,000 new cases of breast cancer in women will be diagnosed in the United States in 2019 and nearly 42,000 women will die from the disease.

 

Click here to learn more.